962 related articles for article (PubMed ID: 16724651)
21. The remission of nephrotic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy.
Goumenos DS; Kalliakmani P; Tsakas S; Sotsiou F; Vlachojannis JG
Clin Nephrol; 2004 Jan; 61(1):17-24. PubMed ID: 14964453
[TBL] [Abstract][Full Text] [Related]
22. The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party.
Cameron JS; Healy MJ; Adu D
Q J Med; 1990 Feb; 74(274):133-56. PubMed ID: 2189149
[TBL] [Abstract][Full Text] [Related]
23. The effect of treatment with prednisolone or cyclophosphamide-warfarin-dipyridamole combination on the outcome of patients with membranous nephropathy.
Shearman JD; Yin ZG; Aarons I; Smith PS; Woodroffe AJ; Clarkson AR
Clin Nephrol; 1988 Dec; 30(6):320-9. PubMed ID: 3243041
[TBL] [Abstract][Full Text] [Related]
24. Long-term follow-up study of IgM associated nephrotic syndrome patients: clinical outcome and prognostic indicators.
Kurathong P; Jesdapatarakul S
J Med Assoc Thai; 2000 Mar; 83(3):315-24. PubMed ID: 10808687
[TBL] [Abstract][Full Text] [Related]
25. Benefit and cost from the long-term use of cyclosporine-A in idiopathic membranous nephropathy.
Kalliakmani P; Koutroulia E; Sotsiou F; Vlachojannis JG; Goumenos DS
Nephrology (Carlton); 2010 Dec; 15(8):762-7. PubMed ID: 21175962
[TBL] [Abstract][Full Text] [Related]
26. Treatment and long-term follow-up of patients with stage II to III idiopathic membranous nephropathy.
Polenakovik MH; Grcevska L
Am J Kidney Dis; 1999 Nov; 34(5):911-7. PubMed ID: 10561149
[TBL] [Abstract][Full Text] [Related]
27. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment.
McIntyre CW; Fluck RJ; Lambie SH
Clin Nephrol; 2001 Sep; 56(3):193-8. PubMed ID: 11597033
[TBL] [Abstract][Full Text] [Related]
28. Beta-2-microglobulin is superior to N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathic membranous nephropathy.
Hofstra JM; Deegens JK; Willems HL; Wetzels JF
Nephrol Dial Transplant; 2008 Aug; 23(8):2546-51. PubMed ID: 18308774
[TBL] [Abstract][Full Text] [Related]
29. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis.
Arends S; Grootscholten C; Derksen RH; Berger SP; de Sévaux RG; Voskuyl AE; Bijl M; Berden JH;
Ann Rheum Dis; 2012 Jun; 71(6):966-73. PubMed ID: 22128082
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcome of patients with idiopathic membranous nephropathy.
Ríhová Z; Merta M; Maixnerová D; Honsová E; Reiterová J; Rysavá R; Zabka J; Tesar V
Prague Med Rep; 2006; 107(2):189-98. PubMed ID: 17066739
[TBL] [Abstract][Full Text] [Related]
31. Prednisolone and chlorambucil therapy for idiopathic membranous nephropathy with progressive renal failure.
Warwick GL; Geddes CG; Boulton-Jones JM
Q J Med; 1994 Apr; 87(4):223-9. PubMed ID: 8208913
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcome of idiopathic membranous nephropathy with nephrotic syndrome.
Zucchelli P; Ponticelli C; Cagnoli L; Passerini P
Nephrol Dial Transplant; 1987; 2(2):73-8. PubMed ID: 3112653
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of idiopathic membranous nephropathy. Is the anti-CD20 antibody rituximab a reasonable option?].
Busch M; Gerth J; Ott U; Schip A; Haufe CC; Gröne HJ; Wolf G
Med Klin (Munich); 2008 Jul; 103(7):519-24. PubMed ID: 18604487
[TBL] [Abstract][Full Text] [Related]
34. [Clinical outcome assessment of membranous nephropathy].
Kumagai T; Shimizu H; Nishi T; Mise N; Tagawa H; Sugimoto T
Nihon Jinzo Gakkai Shi; 2005; 47(8):870-5. PubMed ID: 16408431
[TBL] [Abstract][Full Text] [Related]
35. Treatment of membranous lupus nephritis.
Moroni G; Maccario M; Banfi G; Quaglini S; Ponticelli C
Am J Kidney Dis; 1998 Apr; 31(4):681-6. PubMed ID: 9531186
[TBL] [Abstract][Full Text] [Related]
36. Idiopathic membranous nephropathy and nephrotic syndrome: outcome in the era of evidence-based therapy.
McQuarrie EP; Stirling CM; Geddes CC
Nephrol Dial Transplant; 2012 Jan; 27(1):235-42. PubMed ID: 21558430
[TBL] [Abstract][Full Text] [Related]
37. Treatment of vasculitic IgA nephropathy.
Harper L; Ferreira MA; Howie AJ; Savage CO; Richards NT; Michael J; Adu D
J Nephrol; 2000; 13(5):360-6. PubMed ID: 11063140
[TBL] [Abstract][Full Text] [Related]
38. Prognosis of untreated patients with idiopathic membranous nephropathy.
Schieppati A; Mosconi L; Perna A; Mecca G; Bertani T; Garattini S; Remuzzi G
N Engl J Med; 1993 Jul; 329(2):85-9. PubMed ID: 8510707
[TBL] [Abstract][Full Text] [Related]
39. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis.
Dumoulin A; Hill GS; Montseny JJ; Meyrier A
Am J Kidney Dis; 2003 Jan; 41(1):38-48. PubMed ID: 12500220
[TBL] [Abstract][Full Text] [Related]
40. The therapy of idiopathic membranous glomerulonephritis.
Glassock RJ
Semin Nephrol; 1991 Mar; 11(2):138-47. PubMed ID: 2034923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
